A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion
study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in
participants with advanced solid tumors. The main purpose of this study is to explore the
recommended dosing for BGB-26808.